O
Osamu Tohyama
Researcher at Eisai
Publications - 13
Citations - 1030
Osamu Tohyama is an academic researcher from Eisai. The author has contributed to research in topics: Lenvatinib & Vascular endothelial growth factor. The author has an hindex of 7, co-authored 13 publications receiving 775 citations.
Papers
More filters
Journal ArticleDOI
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama,Junji Matsui,Kotaro Kodama,Naoko Hata-Sugi,Takayuki Kimura,Kiyoshi Okamoto,Yukinori Minoshima,Masao Iwata,Yasuhiro Funahashi +8 more
TL;DR: Data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Journal ArticleDOI
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
Yuji Yamamoto,Junji Matsui,Tomohiro Matsushima,Hiroshi Obaishi,Kazuki Miyazaki,Katsuji Nakamura,Osamu Tohyama,Taro Semba,Atsumi Yamaguchi,Sachi Hoshi,Fusayo Mimura,Toru Haneda,Yoshio Fukuda,Junichi Kamata,Keiko Takahashi,Masayuki Matsukura,Toshiaki Wakabayashi,Makoto Asada,Kenichi Nomoto,Tatsuo Watanabe,Zoltan Dezso,Kentaro Yoshimatsu,Yasuhiro Funahashi,Akihiko Tsuruoka +23 more
TL;DR: Results indicated that Lenvatinib inhibited VEGF- and FGF-driven angiogenesis and showed a broad spectrum of antitumor activity with a wide therapeutic window.
Journal ArticleDOI
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Yasuhiro Funahashi,Kiyoshi Okamoto,Yusuke Adachi,Taro Semba,Mai Uesugi,Yoichi Ozawa,Osamu Tohyama,Taisuke Uehara,Takayuki Kimura,Hideki Watanabe,Makoto Asano,Satoshi Kawano,Xavier Tizon,Paul J. McCracken,Junji Matsui,Ken Aoshima,Kenichi Nomoto,Yoshiya Oda +17 more
TL;DR: It is shown that eribulin induces remodeling of tumor vasculature through a novel antivascular activity in MX‐1 and MDA‐MB‐231 human breast cancer xenograft models, suggesting that Eribulin‐induced remodelling of abnormal tumor vasculation leads to a more functional microenvironment that may reduce the aggressiveness of tumors due to elimination of inner tumor hypoxia.
Journal ArticleDOI
E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models
Takayuki Nakagawa,Osamu Tohyama,Atsumi Yamaguchi,Tomohiro Matsushima,Keiko Takahashi,Setsuo Funasaka,Shuji Shirotori,Makoto Asada,Hiroshi Obaishi +8 more
TL;DR: The results indicate that E7050 is a potent inhibitor of c‐Met and VEGFR‐2 and has therapeutic potential for the treatment of cancer.
Journal ArticleDOI
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Masahiro Matsuki,Yusuke Adachi,Yoichi Ozawa,Takayuki Kimura,Taisuke Hoshi,Kiyoshi Okamoto,Osamu Tohyama,Kaoru Mitsuhashi,Atsumi Yamaguchi,Junji Matsui,Yasuhiro Funahashi +10 more
TL;DR: The results indicated that simultaneous targeting of tumor cell growth and angiogenesis by lenvatinib plus everolimus resulted in enhanced antitumor activity, which underlies its superior anti‐angiogenic activity in human RCC xenograft models.